Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Neuromuscular disease

IVIg for neuromuscular disease—effective but expensive

Nature Reviews Neurology volume 8, pages 303–305 (2012)Cite this article

Subjects

The American Academy of Neurology has published guidelines for intravenous immunoglobulin (IVIg) treatment of neuromuscular diseases. These guidelines differ from those in Europe owing to different conventions for grading of recommendations. Although IVIg is an effective treatment for inflammatory neuropathies and neuromuscular diseases, it is much more expensive than alternative therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Summary of recommendations for IVIg use in neuromuscular disorders.

References

  1. Patwa, H. S., Chaudhry, V., Katzberg, H., Rae-Grant, A. D. & So, Y. T. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 78, 1009–1015 (2012).

    Article  CAS  Google Scholar 

  2. Elovaara, I. et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol. 15, 893–908 (2008).

    Article  CAS  Google Scholar 

  3. Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924–926 (2008).

    Article  Google Scholar 

  4. Griffin, J. W. & Hughes, R. A. Intravenous immunoglobulin for neuromuscular disease: costs, benefits and reimbursement. Nat. Clin. Pract. Neurol. 5, 119 (2009).

    Article  Google Scholar 

  5. Winters, J. L., Brown, D., Hazard, E., Chainani, A. & Andrzejewski, C. Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain–Barré syndrome. BMC Health Serv. Res. 11, 101 (2011).

    Article  Google Scholar 

  6. Blackhouse, G. et al. Cost-utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. Cost Eff. Resour. Alloc. 8, 14–23 (2010).

    Article  Google Scholar 

  7. Provan, D., Nokes, T. J., Agrawal, S., Winer, J. & Wood, P. Clinical guidelines for immunoglobulin use, 2nd Edn. Department of Health[online] (2008).

  8. Wimperis, J. et al. Clinical guidelines for immunoglobulin use, 2nd Edn update. Department of Health[online] (2011).

Download references

Author information

Authors and Affiliations

  1. MRC Centre for Neuromuscular Disease and Cochrane Neuromuscular Disease Group, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK

    Richard A. Hughes & Michael P. Lunn

Authors
  1. Richard A. Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael P. Lunn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard A. Hughes.

Ethics declarations

Competing interests

R. A. Hughes is a consultant for Baxter, CSL Behring, Grifols/Talecris, LFB and Octopharma, and is Editor of the Cochrane Neuromuscular Review Group. M. P. Lunn is a consultant for Baxter and Grifols/Talecris, and is co-Chief Editor of the Cochrane Neuromuscular Review Group.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hughes, R., Lunn, M. IVIg for neuromuscular disease—effective but expensive. Nat Rev Neurol 8, 303–305 (2012). https://doi.org/10.1038/nrneurol.2012.92

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2012.92

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research